Web Analytics

3 Latest Announced Rounds

$1,325.73M Raised in 74 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Asher Biotherapeutics

start up
United States - South San Francisco , California
  • 17/04/2024
  • Series C
  • $55,000,000

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

Related People

Craig GibbsFounder

Craig Gibbs United States - Palo Alto, California


• Ph.D. (Molecular Biology) and M.B.A.
• 31 years of industry experience including 24 years at Genentech and Gilead
• Executive leadership roles spanning Research & Development, Corporate Development and Commercial
• Independent Board member experience for 2 public and 2 private companies plus 1 non-profit
• Therapeutic area knowledge in Infectious Diseases, Liver, Cardiovascular, Respiratory, Inflammation, Oncology
• Scientific expertise in Biochemistry, Molecular Biology, Protein Engineering, Protein Kinases, Blood Coagulation, Virology, Prodrug Pharmacology, Drug Discovery, Drug Development
• >50 scientific publications, 3 issued patents
• Contributed to 10 NDAs, and commercial preparation for 5 product launches
• Participated in 9 corporate acquisitions, 11 in-licensing and 2 out-licensing transactions
• Contributed to raising a combined $361M in Series B, IPO and secondary public financings at Forty Seven
• Contributed to the $4.9B acquisition of Forty Seven by Gilead
• Contributed to raising over $160M in Series A and B financing for Asher Biotherapeutics